Several outlets are highlighting anti-aging biotech companies, with some focusing on their potential to address chronic disease. There are also reports on related investments, including biotech stocks and psychedelic stocks. The field appears to be active, with researchers and investors taking notice, although some studies have faced setbacks, such as a retraction of a gene therapy paper.